Medifast (MED) Beats Q3 Earnings and Revenue Estimates
Medifast (MED) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $2.12 per share a year ago.
Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President-Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Jim Salera - Stephens Inc. Linda Bolton-Weiser - D.A. Davidson Operator Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call.
Medifast Gears Up for Q3 Earnings: Here's What You Should Know
MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications.
Medifast Drives Growth With Weight Loss Transformation Strategies
MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges.
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medifast Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Urges Shareholders To Join An Inquiry Into Medifast, Inc. For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medifast Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Invited To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medifast Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medifast Inc Is Being Investigated For Violating Securities Laws And Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
